Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TherapeuticsMD, Inc. Director's Dealing 2016

May 7, 2016

35134_dirs_2016-05-06_cc98795f-2a4c-4396-b7c8-0aa5461b7a00.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2016-05-06

Reporting Person: Bernick Brian (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-05-06 Common Stock X 61372 $0.4074 Acquired 6557371 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-05-06 Warrant (right to buy) $0.4074 X 61372 Acquired 2021-06-06 Common Stock (61372) Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 297000 Direct
Common Stock 3000 Indirect

Footnotes

F1: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The reporting person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The reporting person disclaims beneficial ownership of TherapeuticsMD, Inc. (the "Company") common stock except to the extent of his pecuniary interest therein.

F2: The reported securities are held by the GP. As disclosed in footnote 1 above, the reporting person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The reporting person disclaims beneficial ownership of the Company common stock held by the GP, except to the extent of his pecuniary interest therein.

F3: The warrant vested upon issuance on June 6, 2011. This warrant was assumed and re-issued pursuant to the Agreement and Plan of Merger among the Company, VitaMedMD, LLC, and VitaMed Acquisition, LLC, dated as of October 4, 2011.

F4: The warrant expires on June 6, 2016, however, due to a scrivener's error, the expiration of the warrant on prior filings was listed as June 6, 2021.